Elevai Labs, Inc. Common Stock (ELAB) 10-Q 11 Dec 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Dec. 11, 2023
Document Information Line Items
Entity Registrant Name	ELEVAI LABS INC.
Trading Symbol	ELAB
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		17,329,615
Amendment Flag	false
Entity Central Index Key	0001840563
Entity Current Reporting Status	No
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-41875
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-1399981
Entity Address, Address Line One	120 Newport Center Drive
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	Newport Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92660
City Area Code	(866)
Local Phone Number	794-4940
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current Assets
Cash	$ 476,855	$ 1,154,901
Receivables, net	8,382	12,854
Prepaids and deposits	292,058	153,422
Inventory, net	499,309	230,145
Total Current Assets	1,276,604	1,551,322
Deposits	10,773	10,773
Property and equipment, net	55,989	53,535
Operating lease right-of-use asset	239,623	276,553
TOTAL ASSETS	1,582,989	1,892,183
Current Liabilities
Accounts payable and accrued liabilities	705,628	256,325
Customer deposits	54,853	10,172
Due to related parties	222,675	142,704
Derivative liabilities	519,509	68,455
Current portion of operating lease liability	140,910	110,616
Total Current Liabilities	1,643,575	588,272
Operating lease liability	103,309	172,601
TOTAL LIABILIITES	1,746,884	760,873
EQUITY (DEFICIT)
Common stock, $0.0001 par value, 300,000,000 shares authorized; 10,118,834 and 9,568,475 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	1,012	957
Additional paid-in capital	5,699,623	3,852,044
Accumulated other comprehensive income	873	111
Accumulated deficit	(5,865,974)	(2,722,373)
TOTAL EQUITY(DEFICIT)	(163,895)	1,131,310
TOTAL LIABILITIES AND EQUITY	1,582,989	1,892,183
Series seed 1 Preferred Stock
EQUITY (DEFICIT)
Preferred stock	21	21
Series seed 2 Preferred Stock
EQUITY (DEFICIT)
Preferred stock	364	364
Series A Preferred Stock
EQUITY (DEFICIT)
Preferred stock	$ 186	$ 186

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	10,118,834	9,568,475
Common stock, shares outstanding	10,118,834	9,568,475
Series seed 1 Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	213,730	213,730
Preferred stock, shares issued	213,730	213,730
Preferred stock, shares outstanding	213,730	213,730
Series seed 2 Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	3,635,252	3,635,252
Preferred stock, shares issued	3,635,252	3,635,252
Preferred stock, shares outstanding	3,635,252	3,635,252
Series A Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	2,982,003	2,982,003
Preferred stock, shares issued	1,861,799	1,861,799
Preferred stock, shares outstanding	1,861,799	1,861,799

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue	$ 554,654	$ 432,122	$ 1,014,004	$ 627,379
Cost of sales	188,509	194,428	341,122	273,480
Gross profit	366,145	237,694	672,882	353,899
Expenses
Depreciation	2,439	1,630	7,824	3,325
Marketing and promotion	99,709	73,273	316,436	134,762
Consulting fees	82,781	109,443	316,468	248,163
Office and administrative	664,922	312,297	1,628,931	639,714
Professional fees	143,654	49,706	450,384	94,865
Investor relations	9,100	18,430	84,820	32,216
Research and development	86,374	89,325	303,769	167,888
Foreign exchange loss (gain)	(3,113)	(465)	(480)	1,392
Travel and entertainment	65,830	55,892	250,000	148,495
Total Expenses	1,151,696	709,531	3,358,152	1,470,820
Net loss before other income (expense)	(785,551)	(471,837)	(2,685,270)	(1,116,921)
Other income (expense)
Loss on sale of equipment				(1,546)
Interest income	25	3,159	5,481	3,245
Interest expense	(5,713)	(646)	(12,758)	(2,628)
Change in fair value of derivative liabilities	8,192	(29,761)	(451,054)	(29,761)
Net loss	(783,047)	(499,085)	(3,143,601)	(1,147,611)
Other comprehensive income (loss)
Currency translation adjustment	387	(226)	762	16
Net loss and comprehensive loss	$ (782,660)	$ (499,311)	$ (3,142,839)	$ (1,147,595)
Basic loss per share (in Dollars per share)	$ (0.078)	$ (0.052)	$ (0.318)	$ (0.12)
Weighted average shares outstanding (in Shares)	10,023,002	9,526,808	9,900,744	9,526,808

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Diluted loss per share	$ (0.078)	$ (0.052)	$ (0.318)	$ (0.120)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($) $ in Thousands	Series Seed 1 Preferred Stock	Series Seed 2 Preferred Stock	Series A Preferred Stock	Series A	Common Stock	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive income	Total
Balance at Dec. 31, 2021	$ 21	$ 364			$ 952	$ 1,371,194	$ (922,105)	$ 202	$ 450,628
Balance (in Shares) at Dec. 31, 2021	213,730	3,635,252			9,526,808
Conversion of promissory note			$ 23			130,860			130,883
Conversion of promissory note (in Shares)			231,828
Private placement			$ 155			2,056,036			2,056,191
Private placement (in Shares)			1,551,703
Obligation to issue Series A shares						35,000			35,000
Share-based compensation						94,099			94,099
Net loss for the period							(1,147,611)		(1,147,611)
Currency translation adjustment								16	16
Balance at Sep. 30, 2022	$ 21	$ 364	$ 178		$ 952	3,687,189	(2,069,716)	218	1,619,206
Balance (in Shares) at Sep. 30, 2022	213,730	3,635,252	1,783,531		9,526,808
Balance at Dec. 31, 2021	$ 21	$ 364			$ 952	1,371,194	(922,105)	202	450,628
Balance (in Shares) at Dec. 31, 2021	213,730	3,635,252			9,526,808
Balance at Dec. 31, 2022	$ 21	$ 364	$ 186		$ 957	3,852,044	(2,722,373)	111	1,131,310
Balance (in Shares) at Dec. 31, 2022	213,730	3,635,252	1,861,799		9,568,475
Balance at Jun. 30, 2022	$ 21	$ 364			$ 952	1,714,664	(1,570,631)	444	145,814
Balance (in Shares) at Jun. 30, 2022	213,730	3,635,252			9,526,808
Conversion of promissory note			$ 23			130,860			130,883
Conversion of promissory note (in Shares)			231,828
Private placement			$ 155			1,796,318			1,796,473
Private placement (in Shares)			1,551,703
Share issuance cost						(25,242)			(25,242)
Series A preferred shares subscription						35,000			35,000
Exercise of stock options									273,981
Share-based compensation						35,589			35,589
Net loss for the period							(499,085)		(499,085)
Currency translation adjustment								(226)	(226)
Balance at Sep. 30, 2022	$ 21	$ 364	$ 178		$ 952	3,687,189	(2,069,716)	218	1,619,206
Balance (in Shares) at Sep. 30, 2022	213,730	3,635,252	1,783,531		9,526,808
Balance at Dec. 31, 2022	$ 21	$ 364	$ 186		$ 957	3,852,044	(2,722,373)	111	$ 1,131,310
Balance (in Shares) at Dec. 31, 2022	213,730	3,635,252	1,861,799		9,568,475
Conversion of promissory note (in Shares)				231,828					231,828
Private placement					$ 49	1,463,537			$ 1,463,586
Private placement (in Shares)					487,859
Exercise of stock options					$ 6	37,494			37,500
Exercise of stock options (in Shares)					62,500
Share-based compensation						346,548			346,548
Net loss for the period							(3,143,601)		(3,143,601)
Currency translation adjustment								762	762
Balance at Sep. 30, 2023	$ 21	$ 364	$ 186		$ 1,012	5,699,623	(5,865,974)	873	(163,895)
Balance (in Shares) at Sep. 30, 2023	213,730	3,635,252	1,861,799		10,118,834
Balance at Jun. 30, 2023	$ 21	$ 364	$ 186		$ 999	5,148,159	(5,082,927)	486	67,288
Balance (in Shares) at Jun. 30, 2023	213,730	3,635,252	1,861,799		9,988,836
Conversion of promissory note
Private placement					$ 13	389,984			389,997
Private placement (in Shares)					129,998
Share-based compensation						161,480			161,480
Net loss for the period							(783,047)		(783,047)
Currency translation adjustment								387	387
Balance at Sep. 30, 2023	$ 21	$ 364	$ 186		$ 1,012	$ 5,699,623	$ (5,865,974)	$ 873	$ (163,895)
Balance (in Shares) at Sep. 30, 2023	213,730	3,635,252	1,861,799		10,118,834

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating activities
Net loss	$ (3,143,601)	$ (1,147,611)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	8,737	3,898
Accrued Interest		2,614
Share-based compensation	346,548	94,099
Straight-line rent expense	(2,068)	7,354
Change in fair value of derivative liabilities	451,054	29,761
Loss on sale of equipment		1,546
Changes in non-cash working capital:
Receivables	4,507	(13,811)
Prepaid expenses and deposits	(138,636)	(127,612)
Inventory	(269,164)	(19,870)
Accounts payable and accrued liabilities	449,281	(5,832)
Customer deposits	44,681	5,992
Due to related parties	80,000	90,000
Cash flows used in operating activities	(2,168,661)	(1,079,472)
Investing activities
Purchase of equipment	(11,191)	(36,927)
Proceeds from sale of equipment		3,500
Cash flows used in investing activities	(11,191)	(33,427)
Financing activities
Proceeds from issuance of common stock and warrants	1,463,585	2,056,191
Exercise of stock options	37,500
Obligation to issue shares		35,000
Proceeds from convertible debenture		183,970
Cash flows provided by financing activities	1,501,085	2,275,161
Effect of exchange rate changes on cash	721	(1,104)
Change in cash	(678,046)	1,161,158
Cash, beginning of period	1,154,901	411,858
Cash, ending of period	476,855	1,573,016
Supplemental cash flow information:
Cash paid for interest	4,898
Cash paid for taxes
Non-cash Investing and Financing transactions:

Organization and Nature of Oper

Organization and Nature of Operations	9 Months Ended
	Sep. 30, 2023
Organization and Nature of Operations [Abstract]
Organization and nature of operations	1. Organization and nature of operations Elevai Labs Inc. (“Elevai”) was incorporated under the laws of the State of Delaware on June 9, 2020. Elevai and its 100% owned subsidiary, Elevai Research Inc. (“Elevai Research”), are collectively referred to in these unaudited condensed consolidated financial statements as “the Company”. The Company is a skincare development company engaged in the design, manufacture, and marketing of skincare products in the skincare industry. The Company’s principal activities are developing and manufacturing skincare products. On November 20, 2023 Elevai Labs Inc. announced the pricing of its initial public offering. The initial public offering consisted of 1,500,000 shares of common stock at a public offering price of $4.00 per share, for total gross proceeds of $6,000,000 before deducting underwriting discounts and offering expenses. The shares of common stock were approved for listing on the Nasdaq Capital Market and commenced trading on November 21, 2023, under the ticker symbol "ELAB". The initial public offering closed on November 24, 2023.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2023
Going Concern [Abstract]
Going Concern	2. Going Concern These unaudited condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders and the ability of the Company to obtain necessary equity financing to continue operations, and ultimately the attainment of profitable operations. As of September 30, 2023 and December 31, 2022, the Company had a net working capital deficit of $366,971, and a positive working capital $963,050, respectively, and has an accumulated deficit of $5,865,974 and $2,722,373, respectively. In addition, as of September 30, 2023, the Company has a total equity deficit of $163,895. Furthermore, for the nine months ended September 30, 2023 and 2022, the Company incurred a net loss of $3,143,601 and $1,147,611 respectively and used $2,168,661 and $1,079,472, respectively of cash flows for operating activities. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The assessment of whether the going concern assumption is appropriate requires management to take into account all available information about the future, which is at least, but not limited to, 12 months from the date the financial statements are issued. The Company is aware that material uncertainties related to events or conditions may cast substantial doubt upon the Company’s ability to continue as a going concern. Management’s plans that alleviate substantial doubt about the Company’s ability to continue as a going concern include raising additional debt or equity financing. In addition, in February 2023, the Company filed its preliminary initial registration (S-1 Form) with the SEC pursuant to its goal of completing an initial public offering (“IPO”). The Company plans to use funds raised in a successful IPO to accelerate new product development, inventory production, increasing its sales force and expanding into new markets. The outbreak of the coronavirus, also known as “COVID-19”, has spread across the globe and is impacting worldwide economic activity. Conditions surrounding the coronavirus continue to rapidly evolve and government authorities have implemented emergency measures to mitigate the spread of the virus. The outbreak and the related mitigation measures may have an adverse impact on global economic conditions as well as on the Company’s business activities. The extent to which the coronavirus may impact the Company’s business activities will depend on future developments, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, business disruptions, and the effectiveness of actions taken in the USA and Canada and other countries to contain and treat the disease. These events are highly uncertain and as such, the Company cannot determine their financial impact at this time. While certain restrictions are presently in the process of being relaxed, it is unclear when the world will return to the previous normal, if ever. This may adversely impact the expected implementation of the Company’s plans moving forward.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with rules and regulations of the Securities and Exchange Commission (“SEC”) and generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and are expressed in United States dollars. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, we have included all adjustments considered necessary for a fair presentation and such adjustments are of a normal recurring nature. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the years ended December 31, 2022 and 2021. The results of operations for the nine months ended September 30, 2023, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2023. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Elevai, and its 100% owned subsidiary, Elevai Research. All intercompany accounts, transactions and profits were eliminated in the unaudited condensed consolidated financial statements. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to revenue recognition, the collectability of receivables, valuation of inventory, fair value of derivative liabilities and stock options, useful lives and recoverability of long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from those estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined. Foreign Currency Translation The Company’s functional and reporting currency is the U.S. dollar. The functional currency of Elevai Research is the Canadian dollar. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets, liabilities, and items recorded in income arising from transactions denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income. The accounts of Elevai Research are translated to U.S. dollars using the current rate method. Accordingly, assets and liabilities are translated into U.S. dollars at the period-end exchange rate while revenues and expenses are translated at the average exchange rates during the period. Related exchange gains and losses are included in a separate component of stockholders’ equity as accumulated other comprehensive income (loss). New Accounting Standards Recently Adopted Accounting Standards In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “Debt—Debt with Conversion and Other Options” and ASC subtopic 815-40 “Hedging—Contracts in Entity’s Own Equity”. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The adoption of this standard did not have a significant impact on the Company’s unaudited condensed consolidated financial statements. In March 2022, the FASB issued ASU 2022-02, ASC Subtopic 326 “Credit Losses”: Troubled Debt Restructurings and Vintage Disclosures. Since the issuance of Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, the Board has provided resources to monitor and assist stakeholders with the implementation of Topic 326. Post-Implementation Review (PIR) activities have included forming a Credit Losses Transition Resource Group, conducting outreach with stakeholders of all types, developing educational materials and staff question-and-answer guidance, conducting educational workshops, and performing an archival review of financial reports. ASU No. 2022-02 is effective for annual and interim periods beginning after December 15, 2022. The adoption of this standard did not have a significant impact on the Company’s unaudited condensed consolidated financial statements. Recently Issued Accounting Standards The Company assesses the adoption impacts of recently issued, but not yet effective, accounting standards by the Financial Accounting Standards Board on the Company’s unaudited condensed consolidated financial statements. In June 2022, the FASB issued ASU 2022-03, ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The FASB is issuing this Update (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. Stakeholders asserted that the language in the illustrative example resulted in diversity in practice on whether the effects of a contractual restriction that prohibits the sale of an equity security should be considered in measuring that equity security’s fair value. Some stakeholders apply a discount to the price of an equity security subject to a contractual sale restriction, whereas other stakeholders consider the application of a discount to be inappropriate under the principles of Topic 820. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company does not expect the standard to have a significant impact on its consolidated financial statements.

Receivables

Receivables	9 Months Ended
	Sep. 30, 2023
Receivables [Abstract]
Receivables	4. Receivables As of September 30, 2023 and December 31 2022, receivables consisted of the following: September 30, December 31, Trade receivable $ 5,692 $ 4,180 Sales taxes receivable 2,690 8,674 $ 8,382 $ 12,854 The Company records sales taxes receivable for recoverable sales taxes paid on eligible purchases in its Canadian subsidiary. As at September 30, 2023, and December 31, 2022, the Company recorded a provision for doubtful accounts of $ nil nil

Prepaids and Deposits

Prepaids and Deposits	9 Months Ended
	Sep. 30, 2023
Prepaids and Deposits [Abstract]
Prepaids and Deposits	5. Prepaids and Deposits As of September 30, 2023 and December 31, 2022, prepaid and deposits consisted of the following: September 30, December 31, Prepaid expenses $ 44,278 $ 89,819 Deposits 21,613 24,376 Deferred share issuance and listing expense 236,940 50,000 $ 302,831 $ 164,195 Prepaids and deposits - current 292,058 153,422 Deposits- non-current 10,773 10,773 As of September 30, 2023 and December 31, 2022, the security deposit on the Company’s long-term lease in the amount of $10,773 is classified as a non-current deposit on the balance sheet.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2023
Inventory [Abstract]
Inventory	6. Inventory As of September 30, 2023 and December 31 2022, inventory consisted of the following: September 30, December 31, Raw materials $ 257,243 $ 81,133 Work in progress 143,166 116,984 Finished goods 98,900 32,028 $ 499,309 $ 230,145 Cost of inventory recognized as expense in cost of sales for the nine months ended September 30, 2023 and 2022, totaled $193,805 and $233,728, respectively. In addition, the cost of inventory relating to samples given out and expensed in marketing and promotion for the nine months ended September 30, 2023 and 2022 totaled $96,184 and $29,437, respectively. As at September 30, 2023, and December 31, 2022, the Company recorded an allowance for inventory of $ nil nil

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2023
Property and Equipment [Abstract]
Property and equipment	7. Property and equipment Equipment Furniture Computers Total Cost Balance, December 31, 2021 $ 32,482 $ - $ - $ 32,482 Additions 24,222 8,365 2,940 35,527 Disposal (6,188 ) - - (6,188 ) Foreign currency translation - - (181 ) (181 ) Balance, December 31, 2022 $ 50,516 $ 8,365 $ 2,759 $ 61,640 Additions 2,658 8,533 - 11,191 Foreign currency translation - - (7 ) (7 ) Balance, September 30, 2023 $ 53,174 $ 16,898 $ 2,752 $ 72,895 Accumulated depreciation Balance, December 31, 2021 $ 2,757 $ - $ - $ 2,757 Depreciation 5,437 548 527 6,512 Disposal (1,142 ) - - (1,142 ) Foreign currency translation - - (22 ) (22 ) Balance, December 31, 2022 $ 7,052 $ 548 $ 505 $ 8,105 Depreciation 6,510 1,811 416 8,737 Foreign currency translation - - (6 ) (6 ) Balance, September 30, 2023 $ 13,562 $ 2,359 $ 914 $ 16,836 Net book value December 31, 2022 $ 43,464 $ 7,817 $ 2,254 $ 53,535 September 30, 2023 $ 39,612 $ 14,540 $ 1,838 $ 55,989 During the nine months ended September 30, 2023 and 2022, the Company capitalized depreciation of $914 and $880, respectively as part of the production of inventory.

Operating lease

Operating lease	9 Months Ended
	Sep. 30, 2023
Operating Lease [Abstract]
Operating lease	8. Operating lease On June 1, 2022, the Company entered into a noncancelable operating lease that includes two property location, one which is being used as the Company’s office and the other as its lab for research and development and the production of inventory. The lease had a commencement date of June 1, 2022 and expires on May 31, 2025, after which the term will continue on a month-to-month basis. On July 3 rd The Company recognized a total lease cost related to its noncancelable operating lease of $103,000 and $42,173, for the nine months ended September 30, 2023 and June 30, 2022, respectively. The lease cost has been allocated as follows based on the square footage of each property location. September 30, September 30, Office space, recorded in office and administration $ 74,641 $ 29,569 Lab space, recorded in research and development 23,705 10,473 Lab space, capitalized to production of inventory 4,655 2,131 $ 103,000 $ 42,173 As of September 30, 2023 and December 31, 2022, the Company recorded a security deposit of $10,773. (Note 5) Future minimum lease payments under the Company’s operating lease that has an initial noncancelable lease term in excess of one year at September 30, 2023 are as follows: As of September 30, 2023 Total 2023 $ 40,430 2024 161,721 2025 67,374 Thereafter - 269,535 Less: Imputed interest (25,316 ) Operating lease liability 244,219 Operating lease lability – current 140,910 Operating lease lability – non-current $ 103,309 The Company used a discount rate of 11.50% upon the remeasurement of the lease liability on July 1, 2023, compared to an original discount rate of 8% on lease commencement, as its incremental cost of borrowing and the remaining lease term as of September 30, 2023, is 1.67 years (December 31, 2022 – 2.42 years).

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	9 Months Ended
	Sep. 30, 2023
Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable and accrued liabilities	9. Accounts payable and accrued liabilities As of September 30, 2023 and December 31, 2022, accounts payable and accrued liabilities consisted of the following: September 30, December 31, Accounts payable $ 573,054 $ 222,461 Accrued liabilities 132,574 33,864 $ 705,628 $ 256,325 As of September 30, 2023 and December 31, 2022, accounts payable and accrued liabilities include $22,212 and $11,621, respectively that is due to related parties in the ordinary course of business.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2023
Notes Payable [Abstract]
Notes payable	10. Notes payable In April and May 2022, the Company issued promissory notes to five investors (including two related parties of the Company) for a total amount of $183,970. The promissory notes carried simple interest at a rate of 8% per annum. On July 15 2022, the promissory notes and accrued interest of $2,614, converted into the Series A financing round in accordance with the original terms of the agreements. The conversion price was set at $0.80 (60% of the Series A preferred shares financing round price) and as a result the noteholders received 231,828 Series A preferred shares. In addition, the conversion terms contained a 100% warrant coverage ratio resulting in the note holders receiving 231,828 common stock purchase warrants with an exercise price of $2.01 (150% of the Series A financing round price).

Derivative Liabilities

Derivative Liabilities	9 Months Ended
	Sep. 30, 2023
Derivative Liabilities [Abstract]
Derivative liabilities	11. Derivative liabilities We analyzed the common stock purchase warrants issued as partial settlement of the promissory notes payable on July 15, 2022 (Note 10), against the requirements of ASC 480, Distinguishing Liabilities from Equity, and determined that the warrants should be classified as financial liabilities since the terms allows for a cashless net share settlement at the option of the holder. ASC 815, Derivatives and Hedging, requires that the warrants be accounted for as derivative liabilities with initial and subsequent measurement at fair value with changes in fair value recorded as other income (expense). A continuity of the Company’s common stock purchase derivative liability warrants is as follows: Derivative December 31, 2021 $ - Addition of new derivatives recognized as partial settlement of promissory notes 55,701 Change in fair value of derivative liabilities 12,754 Outstanding, December 31, 2022 $ 68,455 Change in fair value of derivative liabilities 451,054 Outstanding, September 30, 2023 $ 519,509 We determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes Option Pricing Model to calculate the fair value as of initial recognition and subsequent reporting period. The Black-Scholes Option Pricing Model requires six basic data inputs: the exercise or strike price, expected time to expiration or exercise, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The following assumptions were used in the Black-Scholes option pricing model: September 30, December 31, July 15, Risk-free interest rate 4.80 % 4.73 % 3.12 % Expected life 1 3.58 years 0.75 years 0.6 years Expected dividend rate 0.00 % 0.00 % 0.00 % Expected volatility 100 % 100 % 100.00 % As of September 30, 2023, the following derivative liability warrants were outstanding: Outstanding Expiry date 1 Weighted average exercise price ($) 75,840 April 27, 2027 2.01 63,037 April 27, 2027 2.01 80,388 April 27, 2027 2.01 12,563 April 27, 2027 2.01 231,828 2.01 As of December 31, 2022, the following derivative liability warrants were outstanding: Outstanding Expiry date 1 Weighted average exercise price ($) 75,840 April 27, 2027 2.01 63,037 May 9, 2027 2.01 80,388 May 24, 2027 2.01 12,563 May 25, 2027 2.01 231,828 2.01 As of September 30, 2023 and December 31, 2022, the weighted average life of derivative liability warrants outstanding was 3.58 and 4.36 years, respectively. 1 On April 28, 2023, the Company amended the warrant agreements for the 231,828 derivative liability warrants outstanding. The amendment removed the clause to automatically convert warrants to shares on IPO date and all warrants were given an expiry date of April 27, 2027. This led to an increase in the expected life input in the Black-Scholes model as of September 30, 2023 compared to the December 31, 2022, when the Company used the expected IPO date to calculate the expected life of the warrants.

Equity

Equity	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Equity	12. Equity Common Stock Authorized As of September 30, 2023 and December 31, 2022, the Company had 300,000,000 and 19,000,000 common stock authorized, respectively, each having a par value of $0.0001. Issued and outstanding As of September 30, 2023, and December 31, 2022, the Company had 10,118,834 and 9,568,475 shares issued and outstanding, respectively. Transactions during the nine months ended September 30, 2023 On January 6, 2023, the Company issued 62,500 common stock upon the exercise of 62,500 stock options with an exercise price of $0.60 per common stock for $37,500, of which $6 was recognized in common stock and the remaining $37,494 in additional paid-in capital. On March 2, 2023, the Company issued 250,000 common stock and 250,000 common stock purchase warrants for $750,000, of which $25 was recognized in common stock and the remaining $749,975 in additional paid-in capital. These warrants are accounted for as equity warrants. On April 14, 2023, the Company issued 97,681 common stock, of which $10 was recognized in common stock and the remaining $293,579 in additional paid-in capital. On May 15, 2023, the Company issued 10,000 common stock, of which $1 was recognized in common stock and the remaining $29,999 was recognized in additional paid-in capital. On August 25, 2023, the Company issued 46,666 common stock, of which $5 was recognized in common stock and the remaining $139,995 was recognized in additional paid-in capital. On September 13, 2023, the Company issued 83,882 common stock and 99,998 common stock purchase warrants, of which $8 was recognized in the common stock and the remaining $249,996 was recognized in additional paid-in capital. These warrants are accounted for as equity warrants. Transactions during the nine months ended September 30, 2022. There was no common stock transactions during the nine months ended September 30, 2022. Preferred Stock Authorized As of September 30, 2023 and December 31, 2022, the Company had 213,730 stock of Series Seed 1 preferred stock authorized, each having a par value of $0.0001 per stock. As of September 30, 2023 and December 31, 2022, the Company had 3,635,252 stock of Series Seed 2 preferred stock authorized, each having a par value of $0.0001 per stock. As of September 30, 2023 and December 31, 2022, the Company had 2,982,003 stock of Series A preferred stock authorized, each having a par value of $0.0001 per stock. Issued and outstanding As of September 30, 2023 and December 31, 2022, the Company had 213,730 Series Seed 1 preferred stock issued and outstanding. As of September 30, 2023 and December 31, 2022, the Company had 3,635,252 Series Seed 2 preferred stock issued and outstanding. As of September 30, 2023 and December 31, 2022, the Company had 1,861,799 Series A preferred stock issued and outstanding. Transactions during the nine-month ended September 30, 2023. There was no preferred stock transactions during the nine months ended September 30, 2023 Transactions during the nine-month ended September 30, 2022. On July 15, 2022, the Company closed the first tranche of its Series A Financing and issued 1,090,029 Series A preferred shares for gross proceeds of $1,462,146, of which $109 was recognized in preferred stock and the remaining $1,462,037 in additional paid-in capital. In addition, the Company issued 231,828 Series A preferred shares and 231,828 common stock purchase warrants upon conversion of $186,584 of promissory notes and accrued interest, of which $23 was recognized in preferred stock, $55,701 as derivative liabilities at fair value, and the remaining $130,860 in additional paid-in capital. On July 27, 2022, the Company closed the second tranche of its Series A Financing and issued 349,790 Series A preferred shares for gross proceeds of $469,207, of which $35 was recognized in preferred stock and the remaining $469,172 in additional paid-in capital. On August 4, 2022, the Company closed the third tranche of its Series A Financing and issued 111,884 Series A preferred shares for gross proceeds of $150,080, of which $11 was recognized in preferred stock and the remaining $150,069 in additional paid-in capital . Equity Warrants Transactions during the nine-month ended September 30, 2023. On March 2, 2023, the Company issued 250,000 common stock and 250,000 common stock purchase warrants. Each warrant is exercisable at $3.00 per common stock. The warrants shall be exercisable, in whole or in part at the issue date but such exercisability shall cease upon the date of the Company’s IPO and listing of its common shares on the Nasdaq Capital Market or other Trading Market and shall continue to be exercisable in whole or in part immediately after the Lock-up Period but no later than the Warrant Expiration Date or Accelerated Warrant Expiration Date (the “Exercise Period”). In the event of the Company’s initial public offering and listing of shares of its common stock on a Trading Market, the Company shall notify the holder at least fifteen (15) calendar days prior to the consummation of such IPO. “Trading Market” shall mean a “national securities exchange” that has registered with the SEC under Section 6 of the Securities Exchange Act of 1934. The Expiration Date shall be the earlier of (i) three years and one hundred eighty (180) days from the issue date (the “Warrant Expiration Date”) or (ii) upon the Company’s reasonable judgment and written notice to the purchaser, of the Company’s option to accelerate the Warrant Expiration Date whereby upon purchaser’s receipt of the Company’s written notice of acceleration during the Exercise Period, the Purchaser’s option to exercise any number of warrants shall occur no later than fourteen (14) days following the receipt of the written notice of acceleration (the “Accelerated Warrant Expiration Date”). For the avoidance of doubt, it shall be reasonable for the Company to accelerate the Expiration Date of this warrant to coincide with transactions including, but not limited to (i) a change of control including but not limited to the voluntary or involuntary sale, assignment, transfer or other disposition, or transfer by operation of law, of more than 50% of any direct or indirect equity interest of the Company; or (ii) a subsequent capital financing other than the IPO consisting of but not limited to an offer or proposal for, or indication of interest in, the issuance of debt or the capital stock of the Company. On September 13, 2023, the Company issued 83,332 common stock and 99,998 common stock purchase warrants. Each warrant is exercisable at $3.00 per common stock. The Warrants shall be exercisable, in whole or in part immediately upon issuance, but such exercisability shall cease upon the date of the Company’s initial public offering (the “IPO”) and listing of its Common Shares on the Nasdaq Capital Market or other Trading Market (as defined herein) and will only become exercisable after the expiration of one hundred eighty (180) days following the Company’s initial public offering (the “Lock-up Period”). The expiration date shall be three years and one hundred eighty (180) days following the issuance of the Warrant Shares. Transactions during the nine months ended September 30, 2022. There was no equity warrant activity during the nine months ended September 30, 2022. As of September 30, 2023, the following equity warrants were outstanding: Outstanding Expiry date Weighted average 250,000 August 28, 2026 3.00 99,998 March 12, 2027 3.00 349,998 3.00 As of December 31, 2022, there were no equity warrants outstanding. As of September 30, 2023, and December 31, 2022, the weighted average life of equity warrants outstanding was 3.07 and Nil years Stock Options The Company has a stock option plan included in the Company’s 2020 Equity Incentive Plan (the “Plan”) where the Board of Directors or any of its committees can grant Incentive Stock Options, Nonstatutory Stock Options, and Restricted Stock. The aggregate number of shares allocated and made available for issuance pursuant to stock options granted under the Plan shall not exceed 1,734,188 shares. The plan shall remain in effect until it is terminated by the Board of Directors. Transactions during the nine-month ended September 30, 2023. On February 1, 2023, the Company granted 10,000 stock options with a contractual life of ten years and an exercise price of $5.00 per common stock. These stock options were valued at $10,767 using the Black-Scholes Option Pricing Model. The options vest 25% on the first anniversary of the grant date and the remaining 75% vest evenly over 36 months thereafter. From May 12, 2023 to June 30, 2023, the Company granted 222,500 stock options (includes 80,000 each to two of its newly appointed independent directors) with a contractual life of ten years and an exercise price of $5.00 per common stock. These stock options were valued at $584,787 using the Black-Scholes Option Pricing Model. The options vest 25% on the first vesting date and the remaining 75% vest evenly over 36 months thereafter. On June 30, 2023, the Company cancelled and reissued 80,000 options previously issued to an advisor of the Company upon their appointment as a director effective June 1, 2023. The cancelled and re-issued options had the same exercise price of $5.00 per common stock and the same vesting terms and expiry date, and as such the cancellation and reissuance had no impact on the Company’s consolidated financial statements. On July 1, 2023, the Company granted 1,500 stock options with a contractual life of ten years and an exercise price of $5.00 per common stock. These stock options were valued at $3,940 using the Black-Scholes Option Pricing Model. The options vest 25% on the first vesting date and the remaining 75% vest evenly over 36 months thereafter. Transactions during the nine months ended September 30, 2022. On April 25, 2022, the Company granted 45,000 stock options with a contractual life of ten years and an exercise price of $0.60 per common stock. These stock options were valued at $11,617 using the Black-Scholes Option Pricing Model. The options vest 25% on the first anniversary of the grant date and the remaining 75% vest evenly over 36 months thereafter. On June 1, 2022, the Company granted 16,000 stock options with a contractual life of ten years and an exercise price of $1.34 per common stock. These stock options were valued at $19,393 using the Black-Scholes Option Pricing Model. The options vest 25% on the first anniversary of the grant date and the remaining 75% vest evenly over 36 months thereafter. From July 1, 2022 to September 30, 2022, the Company granted 226,000 stock options a contractual life of ten years and an exercise price of $1.34 per common stock. These stock options were valued at $273,981 using the Black-Scholes Option Pricing Model. The options vest 25% on the first vesting date and the remaining 75% vest evenly over 36 months thereafter. The following assumptions were used in the Black-Scholes option pricing model during the nine months ended September 30, 2023, and year ended December 31, 2022: September 30, December 31, Risk-free interest rate 3.39-3.86 % 2.81% - 4.07 % Expected life 10 years 10 years Expected dividend rate 0.00 % 0.00 % Expected volatility 100 % 100 % Forfeiture rate 0.00 % 0.00 % The continuity of stock options for the period ended September 30, 2023 and year ended December 31, 2022 is summarized below: Number of stock options Weighted average exercise price Outstanding, December 31, 2021 1,133,334 $ 0.60 Granted 412,000 2.19 Forfeited (137,500 ) 0.60 Exercised (41,667 ) 0.60 Outstanding, December 31, 2022 1,366,167 1.08 Granted 234,000 5.00 Exercised (62,500 ) 0.60 Outstanding, September 30, 2023 1,537,667 1.70 As of September 30, 2023, the following options were outstanding, entitling the holders thereof the right to purchase one common stock for each option held as follows: Outstanding Vested Expiry date Weighted average exercise price ($) 841,667 561,117 February 8, 2031 0.60 50,000 33,340 February 27, 2031 0.60 45,000 15,938 April 25, 2032 0.60 16,000 5,000 June 1, 2032 1.34 110,000 32,083 July 1, 2032 1.34 100,000 27,083 August 8, 2032 1.34 16,000 4,000 September 30, 2032 1.34 80,000 20,000 September 30, 2032 5.00 10,000 - October 15, 2032 1.34 10,000 - November 1, 2032 1.34 5,000 - November 1, 2032 5.00 20,000 - December 12, 2032 5.00 10,000 - February 1, 2033 5.00 50,000 - April 16, 2033 5.00 80,000 - May 1, 2033 5.00 80,000 - January 25, 2033 5.00 10,000 - June 27, 2033 5.00 2,500 - July 10, 2033 5.00 1,500 - July 1, 2033 5.00 1,537,667 698,561 1.70 As of September 30, 2023, the weighted average life of stock options outstanding was 8.09 years (December 31, 2022 – 8.58 years). During the nine months ended September 30, 2023 and 2022, the Company recorded $346,549 and $94,099, respectively, in share-based compensation expense, of which $337,551 and $8,998, and $90,271 and $3,828, respectively is included in office and administration and research and development, respectively.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	13. Related Party Transactions Related parties consist of the following individuals and corporations: ● Braeden Lichti, Chairman and former President, significant shareholder through BWL Investments Ltd. Resigned as President effective October 11, 2022. ● Jordan Plews, CEO and Director, significant shareholder through JP Bio Consulting LLC ● Graydon Bensler, CFO and Director ● Yi Guo, Former Director, resigned effective September 29, 2022 ● Tim Sayed, Chief Medical Officer ● Brenda Buechler, Chief Marketing Officer ● Christoph Kraneiss, Chief Commercial Officer ● Jeffrey Parry, Director (appointed June 1, 2023) ● Julie Daley, Director (appointed June 1, 2023) ● Crystal Muilenburg, Director (appointed June 1, 2023) ● GB Capital Ltd., controlled by Graydon Bensler ● JP Bio Consulting LLC, significant shareholder and controlled by Jordan Plews ● BWL Investments Ltd., significant shareholder and controlled by Braeden Lichti ● Northstrive Companies Inc., controlled by Braeden Lichti Key management personnel include those persons having authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company’s Board of Directors, corporate officers, and individuals with more than 10% control. The remuneration of directors and key management personnel is as follows: Three months ended Three months ended Nine months ended Nine months ended Consulting fees $ 51,250 $ 51,250 $ 153,750 $ 147,998 Salaries 159,874 63,784 476,126 252,879 Share-based compensation 124,994 29,860 247,348 80,259 $ 336,118 $ 144,894 $ 877,224 $ 481,136 During the nine months ended September 30, 2023, the Company incurred consulting fees of $63,750 (September 30, 2022 - $57,998) to GB Capital Ltd., a company controlled by Graydon Bensler, CFO and Director. In addition, the Company incurred consulting fees of $90,000 (September 30, 2022 - $90,000) to Northstrive Companies Inc., a company controlled by the Company’s Chairman and former President. Jordan Plews, CEO and Director, earned a Salary of $168,050 and $171,721, respectively during the nine months period ended September 30, 2023 and 2022 (includes employer taxes of $18,050 and $11,720, respectively). Brenda Buechler, Chief Marketing Officer, earned a Salary of $159,950 and $56,803, respectively during the nine month periods ended September 30, 2023 and 2022 (includes employer taxes of $17,446 and $4,303 respectively). Christoph Kraneiss, Chief Commercial Officer, earned a Salary of $148,131 and $24,354, respectively during the nine month periods ended September 30, 2023 and 2022 (includes employer taxes of $13,131 and $1,854, respectively). On February 9, 2021, the Company granted 800,000 stock options to four related parties (200,000 stock options each) with a contractual life of ten years and exercise price of $0.60 per share of common stock. These stock options were valued at $203,972 using the Black-Scholes Option Pricing Model. The options vest 25% on the first anniversary of the grant date and the remaining 75% vest evenly over 36 months thereafter. On June 1, 2023, the Company granted 160,000 stock options to directors of the company (80,000 stock options each) with a contractual life of ten years and exercise price of $5.00 per share of common stock. These stock options were valued at $420,521 using the Black-Scholes Option Pricing Model. The options vest 25% on the first anniversary of the grant date and the remaining 75% vest evenly over 36 months thereafter. On June 1, 2023, the Company cancelled and re-issued 80,000 stock options to a director of the company with a contractual life of ten years and exercise price of $5.00 per share of common stock. The cancelled and re-issued options had the same exercise price of $5.00 per common stock and the same vesting terms and expiry date, and as such the cancellation and reissuance is not expected to impact on the Company’s consolidated financial statements. (Note 12). Details of the fair value of the options granted to each individual and the related expense recorded for the nine month periods ended September 30, 2023 and 2022 are as follow: Nine months ended Nine months ended Grant date fair value of stock options Braeden Lichti, Former Chairman and President $ 5,398 $ 11,571 $ 50,993 Graydon Bensler, CFO and Director 5,398 11,571 50,993 Jordan Plews, CEO and Director 5,398 11,571 50,993 Tim Sayed, Chief Medical Officer 5,398 11.571 50,993 Jeffrey Parry, Director 21,177 - 107,669 Julie Daley, Director 56,022 - 210,245 Crystal Muilenburg, Director 46,725 - 210,245 $ 145,516 $ 46,284 $ 732,131 On July 20, 2021, the Company granted 200,000 stock options to a related party, Yi Guo, former Director, with a contractual life of ten years and exercise price of $0.60 per share of common stock. These stock options were valued at $51,014 using the Black-Scholes Option Pricing Model. The options vest 25% on the first anniversary of the grant date and the remaining 75% vest evenly over 36 months thereafter. On October 17, 2022, Yi Guo resigned from the board of directors of the Company and as a result, 137,500 unvested options were forfeited. The remaining 62,500 vested option remain exercisable for 3 months after the resignation. On January 6, 2023, Yi Guo exercised the remaining 62,500 options. The share-based compensation expense recorded for the nine months ended September 30, 2023 and 2022 relating to these stock options was $ Nil During the second and third quarter of 2022, the Company granted 250,000 stock options to two related parties (150,000 stock options to Brenda Buechler, Chief Marketing Officer, and 100,000 options to Christoph Kraneiss, Chief Commercial Officer) with a contractual life of ten years and weighted average exercise price of $1.22 per share of common stock. These stock options were valued at $264,906 using the Black-Scholes Option Pricing Model. The options vest 25% on the first anniversary of the grant date and the remaining 75% vest evenly over 36 months thereafter. Details of the fair value granted to each individual and the related expense recorded for the nine months ended September 30, 2023 and 2022 is as follow: Nine months ended Nine months ended Grant date fair value of stock options Brenda Buechler, Chief Marketing Officer $ 53,008 $ 22,189 $ 143,679 Christoph Kraneiss, Chief Commercial Officer 48,824 10,362 121,227 $ 101,832 $ 32,551 $ 264,906 As of September 30, 2023 and December 31, 2022, the Company had $222,675 and $142,705, respectively due to companies controlled by Braeden Lichti, of which $12,675 and $22,705, respectively is unsecured, non-interest bearing and are due on demand. The remaining $210,000 and $120,000, respectively due as of September 30, 2023 and December 31, 2022, is payable to Northstrive Companies Inc. for consulting services rendered by Braeden Lichti (the “Fees”). Payment of the Fees will be deferred until the earlier of either (a) the Company raising an aggregate of at least $2,000,000 of equity and/or debt investment from and after October 1, 2022, (b) the Company becomes listed on any established stock exchange or a national market system including without limitation the New York Stock Exchange, the Nasdaq Capital Market of The Nasdaq Stock Market, or (c) the Board determines that the Company has sufficient cash flows to support payment of the foregoing amounts of Fees due at the time of that determination. The Fees earned prior to March 31, 2023 shall be payable in cash payment or in the form of Series A preferred stock priced at $1.34138 per share (the “Original Series A Issue Price”) equal to the value of the Fees then due. While the Fees earned after April 1, 2023 shall be payable in cash payment or in the form of Series A preferred stock priced at $3 per share. As of September 30, 2023, accounts payable and accrued liabilities include $7,442 (December 31, 2022 - $7,165) in consulting fees payable to Graydon Bensler, CFO and Director, $7,831 (December 31, 2022 - $1,485) to companies controlled by Braeden Lichti, and $4,272 (December 31, 2022 - $2,971) to Jordan Plews, CEO and Director, for expenses incurred on behalf of the Company.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies There were no commitments as of September 30, 2023 and December 31, 2022 or during the periods then ended. The Company had an ongoing dispute with a vendor regarding unpaid invoices. The Company disputed the services claimed to have been rendered by the vendor. In May 2023, the Company and the vendor agreed to settle the matter, resulting in the Company agreeing to pay a final settlement of Cnd$12,500 (approximately $9,225), an amount that is significantly less than the unpaid invoices originally claimed by the vendor. The Company included the settlement amount in accrued liabilities as of December 31, 2022 and the amount was paid over to the vendor during the nine months ended September 30, 2023.

Concentrations

Concentrations	9 Months Ended
	Sep. 30, 2023
Concentrations [Abstract]
Concentrations	15. Concentrations Customers During the nine month period ended September 30, 2023, the Company recorded 14% of its revenue from its largest customer. The Company’s largest customer relates to sales to a wholesaler during the period. During the nine months ended September 30, 2022, the Company recorded 55% of its revenue from a single customer. The company’s largest customer relates to sales to a wholesaler during the period. As of September 30, 2023 and December 31, 2022, the Company had $49 and $ nil nil The Company expects its dependence on major customers to decrease over time as it enters into additional distributor agreements and builds out its sales team. Suppliers During the nine month period ended September 30, 2023 and 2022, the Company had 3 key suppliers that represented approximately 66% and 72%, respectively, of the cost incurred in the purchase and production of inventory. The table below represents a breakdown of each supplier as a percentage of the cost incurred (Suppliers are shown from largest to smallest and does not necessarily represent the same suppliers period over period): Nine Months Ended Nine Months Ended Supplier 1 26 % 46 % Supplier 2 23 % 14 % Supplier 2 17 % 12 % 66 % 72 % The Company continually evaluates the performance of its suppliers and the availability of alternatives to substitute or supplement its inventory production supply chain. The Company believes that a breakdown in supply from one of its key suppliers would be overcome in a short amount of time given the availability of alternatives.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	16. Subsequent Events Management has evaluated events subsequent to the period ended September 30, 2023, up to December 11, 2023, and has identified the following transactions or other events that may require adjustment of and/or disclosure in the condensed consolidated financial statements. Initial Public Offering On November 21, 2023, the Company successfully completed its Initial Public Offering (IPO) and commenced trading on the NASDAQ Stock Market under the ticker symbol ELAB.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with rules and regulations of the Securities and Exchange Commission (“SEC”) and generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and are expressed in United States dollars. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, we have included all adjustments considered necessary for a fair presentation and such adjustments are of a normal recurring nature. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the years ended December 31, 2022 and 2021. The results of operations for the nine months ended September 30, 2023, are not necessarily indicative of the results to be expected for the full fiscal year ending December 31, 2023.
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Elevai, and its 100% owned subsidiary, Elevai Research. All intercompany accounts, transactions and profits were eliminated in the unaudited condensed consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to revenue recognition, the collectability of receivables, valuation of inventory, fair value of derivative liabilities and stock options, useful lives and recoverability of long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from those estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined.
Foreign Currency Translation	Foreign Currency Translation The Company’s functional and reporting currency is the U.S. dollar. The functional currency of Elevai Research is the Canadian dollar. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Non-monetary assets, liabilities, and items recorded in income arising from transactions denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income. The accounts of Elevai Research are translated to U.S. dollars using the current rate method. Accordingly, assets and liabilities are translated into U.S. dollars at the period-end exchange rate while revenues and expenses are translated at the average exchange rates during the period. Related exchange gains and losses are included in a separate component of stockholders’ equity as accumulated other comprehensive income (loss).
New Accounting Standards	New Accounting Standards Recently Adopted Accounting Standards In August 2020, the FASB issued ASU 2020-06, ASC Subtopic 470-20 “Debt—Debt with Conversion and Other Options” and ASC subtopic 815-40 “Hedging—Contracts in Entity’s Own Equity”. The standard reduced the number of accounting models for convertible debt instruments and convertible preferred stock. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting; and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The adoption of this standard did not have a significant impact on the Company’s unaudited condensed consolidated financial statements. In March 2022, the FASB issued ASU 2022-02, ASC Subtopic 326 “Credit Losses”: Troubled Debt Restructurings and Vintage Disclosures. Since the issuance of Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, the Board has provided resources to monitor and assist stakeholders with the implementation of Topic 326. Post-Implementation Review (PIR) activities have included forming a Credit Losses Transition Resource Group, conducting outreach with stakeholders of all types, developing educational materials and staff question-and-answer guidance, conducting educational workshops, and performing an archival review of financial reports. ASU No. 2022-02 is effective for annual and interim periods beginning after December 15, 2022. The adoption of this standard did not have a significant impact on the Company’s unaudited condensed consolidated financial statements. Recently Issued Accounting Standards The Company assesses the adoption impacts of recently issued, but not yet effective, accounting standards by the Financial Accounting Standards Board on the Company’s unaudited condensed consolidated financial statements. In June 2022, the FASB issued ASU 2022-03, ASC Subtopic 820 “Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. The FASB is issuing this Update (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. Stakeholders asserted that the language in the illustrative example resulted in diversity in practice on whether the effects of a contractual restriction that prohibits the sale of an equity security should be considered in measuring that equity security’s fair value. Some stakeholders apply a discount to the price of an equity security subject to a contractual sale restriction, whereas other stakeholders consider the application of a discount to be inappropriate under the principles of Topic 820. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company does not expect the standard to have a significant impact on its consolidated financial statements.

Receivables (Tables)

Receivables (Tables)	9 Months Ended
	Sep. 30, 2023
Receivables [Abstract]
Schedule of Receivables	As of September 30, 2023 and December 31 2022, receivables consisted of the following: September 30, December 31, Trade receivable $ 5,692 $ 4,180 Sales taxes receivable 2,690 8,674 $ 8,382 $ 12,854

Prepaids and Deposits (Tables)

Prepaids and Deposits (Tables)	9 Months Ended
	Sep. 30, 2023
Prepaids and Deposits [Abstract]
Schedule of Prepaid and Deposits	As of September 30, 2023 and December 31, 2022, prepaid and deposits consisted of the following: September 30, December 31, Prepaid expenses $ 44,278 $ 89,819 Deposits 21,613 24,376 Deferred share issuance and listing expense 236,940 50,000 $ 302,831 $ 164,195 Prepaids and deposits - current 292,058 153,422 Deposits- non-current 10,773 10,773

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2023
Schedule of Inventory [Abstract]
Schedule of Inventory	As of September 30, 2023 and December 31 2022, inventory consisted of the following: September 30, December 31, Raw materials $ 257,243 $ 81,133 Work in progress 143,166 116,984 Finished goods 98,900 32,028 $ 499,309 $ 230,145

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2023
Property and Equipment [Abstract]
Schedule of Property and Equipment	Equipment Furniture Computers Total Cost Balance, December 31, 2021 $ 32,482 $ - $ - $ 32,482 Additions 24,222 8,365 2,940 35,527 Disposal (6,188 ) - - (6,188 ) Foreign currency translation - - (181 ) (181 ) Balance, December 31, 2022 $ 50,516 $ 8,365 $ 2,759 $ 61,640 Additions 2,658 8,533 - 11,191 Foreign currency translation - - (7 ) (7 ) Balance, September 30, 2023 $ 53,174 $ 16,898 $ 2,752 $ 72,895 Accumulated depreciation Balance, December 31, 2021 $ 2,757 $ - $ - $ 2,757 Depreciation 5,437 548 527 6,512 Disposal (1,142 ) - - (1,142 ) Foreign currency translation - - (22 ) (22 ) Balance, December 31, 2022 $ 7,052 $ 548 $ 505 $ 8,105 Depreciation 6,510 1,811 416 8,737 Foreign currency translation - - (6 ) (6 ) Balance, September 30, 2023 $ 13,562 $ 2,359 $ 914 $ 16,836 Net book value December 31, 2022 $ 43,464 $ 7,817 $ 2,254 $ 53,535 September 30, 2023 $ 39,612 $ 14,540 $ 1,838 $ 55,989

Operating lease (Tables)

Operating lease (Tables)	9 Months Ended
	Sep. 30, 2023
Operating Lease [Abstract]
Schedule of Lease Cost	The lease cost has been allocated as follows based on the square footage of each property location. September 30, September 30, Office space, recorded in office and administration $ 74,641 $ 29,569 Lab space, recorded in research and development 23,705 10,473 Lab space, capitalized to production of inventory 4,655 2,131 $ 103,000 $ 42,173
Schedule of Future Minimum Lease Payments	Future minimum lease payments under the Company’s operating lease that has an initial noncancelable lease term in excess of one year at September 30, 2023 are as follows: As of September 30, 2023 Total 2023 $ 40,430 2024 161,721 2025 67,374 Thereafter - 269,535 Less: Imputed interest (25,316 ) Operating lease liability 244,219 Operating lease lability – current 140,910 Operating lease lability – non-current $ 103,309

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Accounts Payable and Accrued Liabilities [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	As of September 30, 2023 and December 31, 2022, accounts payable and accrued liabilities consisted of the following: September 30, December 31, Accounts payable $ 573,054 $ 222,461 Accrued liabilities 132,574 33,864 $ 705,628 $ 256,325

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Derivative Liabilities (Tables) [Line Items]
Schedule of Common Stock Purchase Derivative Liability Warrants	A continuity of the Company’s common stock purchase derivative liability warrants is as follows: Derivative December 31, 2021 $ - Addition of new derivatives recognized as partial settlement of promissory notes 55,701 Change in fair value of derivative liabilities 12,754 Outstanding, December 31, 2022 $ 68,455 Change in fair value of derivative liabilities 451,054 Outstanding, September 30, 2023 $ 519,509
Schedule of Black-Scholes Option Pricing Model	The following assumptions were used in the Black-Scholes option pricing model during the nine months ended September 30, 2023, and year ended December 31, 2022: September 30, December 31, Risk-free interest rate 3.39-3.86 % 2.81% - 4.07 % Expected life 10 years 10 years Expected dividend rate 0.00 % 0.00 % Expected volatility 100 % 100 % Forfeiture rate 0.00 % 0.00 %
Derivative liabilities [Member]
Derivative Liabilities (Tables) [Line Items]
Schedule of Black-Scholes Option Pricing Model	The following assumptions were used in the Black-Scholes option pricing model: September 30, December 31, July 15, Risk-free interest rate 4.80 % 4.73 % 3.12 % Expected life 1 3.58 years 0.75 years 0.6 years Expected dividend rate 0.00 % 0.00 % 0.00 % Expected volatility 100 % 100 % 100.00 % 1 On April 28, 2023, the Company amended the warrant agreements for the 231,828 derivative liability warrants outstanding. The amendment removed the clause to automatically convert warrants to shares on IPO date and all warrants were given an expiry date of April 27, 2027. This led to an increase in the expected life input in the Black-Scholes model as of September 30, 2023 compared to the December 31, 2022, when the Company used the expected IPO date to calculate the expected life of the warrants.
Schedule of Derivative Liability Warrants Outstanding	As of September 30, 2023, the following derivative liability warrants were outstanding: Outstanding Expiry date 1 Weighted average exercise price ($) 75,840 April 27, 2027 2.01 63,037 April 27, 2027 2.01 80,388 April 27, 2027 2.01 12,563 April 27, 2027 2.01 231,828 2.01 Outstanding Expiry date 1 Weighted average exercise price ($) 75,840 April 27, 2027 2.01 63,037 May 9, 2027 2.01 80,388 May 24, 2027 2.01 12,563 May 25, 2027 2.01 231,828 2.01 1 On April 28, 2023, the Company amended the warrant agreements for the 231,828 derivative liability warrants outstanding. The amendment removed the clause to automatically convert warrants to shares on IPO date and all warrants were given an expiry date of April 27, 2027. This led to an increase in the expected life input in the Black-Scholes model as of September 30, 2023 compared to the December 31, 2022, when the Company used the expected IPO date to calculate the expected life of the warrants.

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Schedule of Equity Warrants	As of September 30, 2023, the following equity warrants were outstanding: Outstanding Expiry date Weighted average 250,000 August 28, 2026 3.00 99,998 March 12, 2027 3.00 349,998 3.00
Schedule of Black-Scholes Option Pricing Model	The following assumptions were used in the Black-Scholes option pricing model during the nine months ended September 30, 2023, and year ended December 31, 2022: September 30, December 31, Risk-free interest rate 3.39-3.86 % 2.81% - 4.07 % Expected life 10 years 10 years Expected dividend rate 0.00 % 0.00 % Expected volatility 100 % 100 % Forfeiture rate 0.00 % 0.00 %
Schedule of Stock Options	The continuity of stock options for the period ended September 30, 2023 and year ended December 31, 2022 is summarized below: Number of stock options Weighted average exercise price Outstanding, December 31, 2021 1,133,334 $ 0.60 Granted 412,000 2.19 Forfeited (137,500 ) 0.60 Exercised (41,667 ) 0.60 Outstanding, December 31, 2022 1,366,167 1.08 Granted 234,000 5.00 Exercised (62,500 ) 0.60 Outstanding, September 30, 2023 1,537,667 1.70
Schedule of Right To Purchase One Common Stock Option Held	As of September 30, 2023, the following options were outstanding, entitling the holders thereof the right to purchase one common stock for each option held as follows: Outstanding Vested Expiry date Weighted average exercise price ($) 841,667 561,117 February 8, 2031 0.60 50,000 33,340 February 27, 2031 0.60 45,000 15,938 April 25, 2032 0.60 16,000 5,000 June 1, 2032 1.34 110,000 32,083 July 1, 2032 1.34 100,000 27,083 August 8, 2032 1.34 16,000 4,000 September 30, 2032 1.34 80,000 20,000 September 30, 2032 5.00 10,000 - October 15, 2032 1.34 10,000 - November 1, 2032 1.34 5,000 - November 1, 2032 5.00 20,000 - December 12, 2032 5.00 10,000 - February 1, 2033 5.00 50,000 - April 16, 2033 5.00 80,000 - May 1, 2033 5.00 80,000 - January 25, 2033 5.00 10,000 - June 27, 2033 5.00 2,500 - July 10, 2033 5.00 1,500 - July 1, 2033 5.00 1,537,667 698,561 1.70

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Schedule of Remuneration of Directors and Key Management Personnel	The remuneration of directors and key management personnel is as follows: Three months ended Three months ended Nine months ended Nine months ended Consulting fees $ 51,250 $ 51,250 $ 153,750 $ 147,998 Salaries 159,874 63,784 476,126 252,879 Share-based compensation 124,994 29,860 247,348 80,259 $ 336,118 $ 144,894 $ 877,224 $ 481,136
Schedule of fair value of the options granted to each individual and the related expense	Details of the fair value of the options granted to each individual and the related expense recorded for the nine month periods ended September 30, 2023 and 2022 are as follow: Nine months ended Nine months ended Grant date fair value of stock options Braeden Lichti, Former Chairman and President $ 5,398 $ 11,571 $ 50,993 Graydon Bensler, CFO and Director 5,398 11,571 50,993 Jordan Plews, CEO and Director 5,398 11,571 50,993 Tim Sayed, Chief Medical Officer 5,398 11.571 50,993 Jeffrey Parry, Director 21,177 - 107,669 Julie Daley, Director 56,022 - 210,245 Crystal Muilenburg, Director 46,725 - 210,245 $ 145,516 $ 46,284 $ 732,131
Schedule of Fair Value Granted to Each Individual and the Related Expense	Details of the fair value granted to each individual and the related expense recorded for the nine months ended September 30, 2023 and 2022 is as follow: Nine months ended Nine months ended Grant date fair value of stock options Brenda Buechler, Chief Marketing Officer $ 53,008 $ 22,189 $ 143,679 Christoph Kraneiss, Chief Commercial Officer 48,824 10,362 121,227 $ 101,832 $ 32,551 $ 264,906

Concentrations (Tables)

Concentrations (Tables)	9 Months Ended
	Sep. 30, 2023
Concentrations [Abstract]
Schedule of Suppliers Percentage of Cost	The table below represents a breakdown of each supplier as a percentage of the cost incurred (Suppliers are shown from largest to smallest and does not necessarily represent the same suppliers period over period): Nine Months Ended Nine Months Ended Supplier 1 26 % 46 % Supplier 2 23 % 14 % Supplier 2 17 % 12 % 66 % 72 %

Organization and Nature of Op_2

Organization and Nature of Operations (Details) - USD ($)

1 Months Ended

Jun. 09, 2020

Nov. 20, 2023

Sep. 30, 2023

Sep. 13, 2023

Aug. 25, 2023

Jul. 01, 2023

Jun. 30, 2023

May 15, 2023

Apr. 14, 2023

Mar. 02, 2023

Jan. 06, 2023

Dec. 31, 2022

Organization and Nature of Operations [Line Items]

Ownership percentage

100%

Common stock

10,118,834

83,882

46,666

10,000

97,681

250,000

62,500

9,568,475

Price per share

$ 5

$ 5

IPO [Member]

Organization and Nature of Operations [Line Items]

Common stock

1,500,000

Price per share

$ 4

Gross proceeds

$ 6,000,000

Going Concern (Details)

Going Concern (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Going Concern [Abstract]
Working capital deficit	$ 366,971			$ 963,050
Accumulated deficit	(5,865,974)			(2,722,373)
Equity deficit	(163,895)	$ 1,619,206	$ 67,288	$ 1,131,310	$ 145,814	$ 450,628
Net loss	3,143,601	1,147,611
Operating activities	$ 2,168,661	$ 1,079,472

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details)	Sep. 30, 2023
Elevai Research Inc [Member]
Summary of Significant Accounting Policies [Line Items]
Owners Percentage	100%

Receivables (Details)

Receivables (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Receivables [Abstract]
Provision for doubtful accounts

Receivables (Details) - Schedul

Receivables (Details) - Schedule of Receivables - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Schedule of Receivables [Abstract]
Trade receivable	$ 5,692	$ 4,180
Sales taxes receivable	2,690	8,674
Total	$ 8,382	$ 12,854

Prepaids and Deposits (Details)

Prepaids and Deposits (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Prepaids and Deposits [Line Items]
Long term lease	$ 10,773	$ 10,773

Prepaids and Deposits (Detail_2

Prepaids and Deposits (Details) - Schedule of Prepaid and Deposits - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Schedule of Prepaid And Deposits [Abstract]
Prepaid expenses	$ 44,278	$ 89,819
Deposits	21,613	24,376
Deferred share issuance and listing expense	236,940	50,000
Prepaid and deposits	302,831	164,195
Prepaids and deposits - current	292,058	153,422
Deposits- non-current	$ 10,773	$ 10,773

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Inventory [Abstract]
Cost of inventory	$ 193,805	$ 233,728
Marketing and promotion expense	96,184	29,437
Allowance for inventory

Inventory (Details) - Schedule

Inventory (Details) - Schedule of Inventory - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory [Line Items]
Total inventory	$ 499,309	$ 230,145
Raw Materials [Member]
Inventory [Line Items]
Total inventory	257,243	81,133
Work in progress [Member]
Inventory [Line Items]
Total inventory	143,166	116,984
Finished goods [Member]
Inventory [Line Items]
Total inventory	$ 98,900	$ 32,028

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022
Property and Equipment [Abstract]
Capitalized depreciation	$ 914	$ 880

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Cost
Total Cost beginning	$ 61,640	$ 32,482
Total Additions	11,191	35,527
Total, Disposal cost		(6,188)
Total Foreign currency translation cost	(7)	(181)
Total Cost ending	72,895	61,640
Accumulated depreciation
Total Accumulated depreciation beginning	8,105	2,757
Total Depreciation	8,737	6,512
Total, Disposal		(1,142)
Total Foreign currency translation	(6)	(22)
Computers, Accumulated depreciation ending	914
Total Accumulated depreciation ending	16,836	8,105
Equipment, Net book value beginning	53,535
Total Net book value beginning	53,535
Equipment, Net book value ending	55,989	53,535
Total Net book value ending	55,989	53,535
Equipment [Member]
Cost
Equipment, Cost beginning	50,516	32,482
Equipment, Additions	2,658	24,222
Equipment, Disposal cost		(6,188)
Equipment, Foreign currency translation cost
Equipment, Cost ending	53,174	50,516
Accumulated depreciation
Equipment, Accumulated depreciation beginning	7,052	2,757
Equipment, Depreciation	6,510	5,437
Equipment, Disposal		(1,142)
Equipment, Foreign currency translation
Equipment, Accumulated depreciation ending	13,562	7,052
Equipment, Net book value beginning	43,464
Equipment, Net book value ending	39,612	43,464
Furniture and Fixtures [Member]
Cost
Furniture and Fixtures, Cost beginning	8,365
Furniture and Fixtures, Additions	8,533	8,365
Furniture and Fixtures, Disposal cost
Furniture and Fixtures, Foreign currency translation cost
Furniture and Fixtures, Cost ending	16,898	8,365
Accumulated depreciation
Furniture and Fixtures, Accumulated depreciation beginning	548
Furniture and Fixtures, Depreciation	1,811	548
Furniture and Fixtures, Disposal
Furniture and Fixtures, Foreign currency translation
Furniture and Fixtures, Accumulated depreciation ending	2,359	548
Furniture and Fixtures, Net book value beginning	7,817
Furniture and Fixtures, Net book value ending	14,540	7,817
Computers [Member]
Cost
Computers, Cost beginning	2,759
Computers, Additions,		2,940
Computers, Disposal cost
Computers, Foreign currency translation cost	(7)	(181)
Computers, Cost ending	2,752	2,759
Accumulated depreciation
Computers, Accumulated depreciation beginning	505
Computers, Depreciation	416	527
Computers, Disposal
Computers, Foreign currency translation	(6)	(22)
Computers, Accumulated depreciation ending	914	505
Computers, Net book value beginning	2,254
Computers, Net book value ending	$ 1,838	$ 2,254

Operating lease (Details)

Operating lease (Details) - USD ($) $ in Thousands		6 Months Ended	9 Months Ended		30 Months Ended
	Jul. 01, 2023	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2025	Dec. 31, 2022
Operating lease (Details) [Line Items]
Rent increased		$ 10,773
Increase lease liability	$ 47,986
Operating lease			$ 103,000	$ 42,173
Security deposit			$ 10,773			$ 10,773
Operating lease term			1 year
Discount rate of lease liability			11.50%
Percentage of discount rate			8%
Remaining lease term			1 year 8 months 1 day			2 years 5 months 1 day
Forecast [Member]
Operating lease (Details) [Line Items]
Rent increased					$ 13,477

Operating lease (Details) - Sch

Operating lease (Details) - Schedule of Lease Cost - Lease Cost [Member] - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating lease (Details) - Schedule of Lease Cost [Line Items]
Office space, recorded in office and administration	$ 74,641	$ 29,569
Lab space, recorded in research and development	23,705	10,473
Lab space, capitalized to production of inventory	4,655	2,131
Operating lease	$ 103,000	$ 42,173

Operating lease (Details) - S_2

Operating lease (Details) - Schedule of Future Minimum Lease Payments - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Schedule of Future Minimum Lease Payments [Abstract]
2023	$ 40,430
2024	161,721
2025	67,374
Thereafter
Total lease payment	269,535
Less: Imputed interest	(25,316)
Operating lease liability	244,219
Operating lease lability – current	140,910	$ 110,616
Operating lease lability – non-current	$ 103,309

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Related Party [Member]
Accounts Payable and Accrued Liabilities [Line Items]
Accounts payable and accrued liabilities	$ 22,212	$ 11,621

Accounts Payable and Accrued _4

Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable	$ 573,054	$ 222,461
Accrued liabilities	132,574	33,864
Total	$ 705,628	$ 256,325

Notes Payable (Details)

Notes Payable (Details) - USD ($)		9 Months Ended
	Jul. 15, 2022	Sep. 30, 2023	May 31, 2022	Apr. 30, 2022
Notes Payable (Details) [Line Items]
Notes payable total amount (in Dollars)			$ 183,970	$ 183,970
Interest rate percentage		8%
Conversion price (in Dollars per share)		$ 0.8
Financing percentage		150%
Noteholders received (in Shares)		231,828
Conversion terms		100%
Exercise price (in Dollars per share)		$ 2.01
Notes Payable [Member]
Notes Payable (Details) [Line Items]
Accrued interest (in Dollars)	$ 2,614
Series A Preferred Shares [Member]
Notes Payable (Details) [Line Items]
Financing percentage		60%
Noteholders received (in Shares)		231,828

Derivative Liabilities (Details

Derivative Liabilities (Details) - shares		9 Months Ended	12 Months Ended
	Apr. 28, 2023	Sep. 30, 2023	Dec. 31, 2022
Derivative Liabilities [Line Items]
Weighted average life of warrants outstanding		3 years 6 months 29 days	4 years 4 months 9 days
Derivative liability warrants outstanding (in Shares)	231,828
Expected life of the warrants	Apr. 27, 2027

Derivative Liabilities (Detai_2

Derivative Liabilities (Details) - Schedule of Common Stock Purchase Derivative Liability Warrants - Derivative Liabilities [Member] - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Derivative Liabilities (Details) - Schedule of Common Stock Purchase Derivative Liability Warrants [Line Items]
Derivative liabilities outstanding, Beginning balance	$ 68,455
Addition of new derivatives recognized as partial settlement of promissory notes		55,701
Change in fair value of derivative liabilities	451,054	12,754
Derivative liabilities outstanding, Ending balance	$ 519,509	$ 68,455

Derivative Liabilities (Detai_3

Derivative Liabilities (Details) - Schedule of Black-Scholes Option Pricing Model - Black-Scholes [Member]		6 Months Ended	9 Months Ended	12 Months Ended
		Jul. 15, 2022	Sep. 30, 2023	Dec. 31, 2022
Derivative Liabilities (Details) - Schedule of Black-Scholes Option Pricing Model [Line Items]
Risk-free interest rate		3.12%	4.80%	4.73%
Expected life	[1]	7 months 6 days	3 years 6 months 29 days	9 months
Expected dividend rate		0%	0%	0%
Expected volatility		100%	100%	100%
[1]On April 28, 2023, the Company amended the warrant agreements for the 231,828 derivative liability warrants outstanding. The amendment removed the clause to automatically convert warrants to shares on IPO date and all warrants were given an expiry date of April 27, 2027. This led to an increase in the expected life input in the Black-Scholes model as of September 30, 2023 compared to the December 31, 2022, when the Company used the expected IPO date to calculate the expected life of the warrants.

Derivative Liabilities (Detai_4

Derivative Liabilities (Details) - Schedule of Derivative Liability Warrants Outstanding - Warrant [Member] - $ / shares		9 Months Ended	12 Months Ended
		Sep. 30, 2023	Dec. 31, 2022
Derivative Liabilities (Details) - Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding		231,828	231,828
Weighted average exercise price		$ 2.01	$ 2.01
April 27, 2027 [Member]
Derivative Liabilities (Details) - Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding		75,840	75,840
Expiry date	[1]	Apr. 27, 2027	Apr. 27, 2027
Weighted average exercise price		$ 2.01	$ 2.01
April 27, 2027 One [Member]
Derivative Liabilities (Details) - Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding		63,037
Expiry date	[1]	Apr. 27, 2027
Weighted average exercise price		$ 2.01
April 27, 2027 Two [Member]
Derivative Liabilities (Details) - Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding		80,388
Expiry date	[1]	Apr. 27, 2027
Weighted average exercise price		$ 2.01
April 27, 2027 Three [Member]
Derivative Liabilities (Details) - Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding		12,563
Expiry date	[1]	Apr. 27, 2027
Weighted average exercise price		$ 2.01
May 9, 2027 [Member]
Derivative Liabilities (Details) - Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding			63,037
Expiry date	[1]		May 09, 2027
Weighted average exercise price			$ 2.01
May 24, 2027 [Member]
Derivative Liabilities (Details) - Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding			80,388
Expiry date	[1]		May 24, 2027
Weighted average exercise price			$ 2.01
May 25, 2027 [Member]
Derivative Liabilities (Details) - Schedule of Derivative Liability Warrants Outstanding [Line Items]
Outstanding			12,563
Expiry date	[1]		May 25, 2027
Weighted average exercise price			$ 2.01
[1]On April 28, 2023, the Company amended the warrant agreements for the 231,828 derivative liability warrants outstanding. The amendment removed the clause to automatically convert warrants to shares on IPO date and all warrants were given an expiry date of April 27, 2027. This led to an increase in the expected life input in the Black-Scholes model as of September 30, 2023 compared to the December 31, 2022, when the Company used the expected IPO date to calculate the expected life of the warrants.

Equity (Details)

Equity (Details) - USD ($)																2 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 13, 2023	Aug. 25, 2023	Jul. 01, 2023	Jun. 30, 2023	Jun. 01, 2023	May 15, 2023	Apr. 14, 2023	Mar. 02, 2023	Feb. 01, 2023	Jan. 06, 2023	Jul. 15, 2022	Jun. 01, 2022	Apr. 25, 2022	Jul. 20, 2021	Feb. 09, 2021	Jun. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Aug. 04, 2022	Jul. 27, 2022
Equity [Line Items]
Common stock, shares authorized																		300,000,000		300,000,000
warrant exercisable per share (in Dollars per share)								$ 3										$ 0.0001		$ 0.0001
Common stock, shares issued	83,882	46,666				10,000	97,681	250,000		62,500								10,118,834		9,568,475
Common stock, shares outstanding																		10,118,834		9,568,475
Stock options, shares										62,500
Exercise price per share (in Dollars per share)									$ 5	$ 0.6		$ 1.34	$ 0.6			$ 5	$ 1.34
Common stock, value (in Dollars)										$ 37,500,000								$ 1,012,000		$ 957,000
Stock options value (in Dollars)			$ 3,940,000						$ 10,767,000			$ 19,393,000	$ 11,617,000			$ 584,787,000	$ 273,981,000	37,500,000
Number of common stock warrant purchase	99,998							250,000
Common stock purchase (in Dollars)								$ 750,000,000
Proceeds from Issuance of Common Stock (in Dollars)																		$ 1,463,585,000	$ 2,056,191,000
Preferred stock, shares issued											231,828
Additional paid-in capital (in Dollars)											$ 130,860,000
Conversion amount (in Dollars)											186,584,000
Exercisable price per share (in Dollars per share)	$ 3
Warrants outstanding term																		3 years 25 days
Stock options shares																		1,734,188
Granted stock options			1,500						10,000			16,000	45,000			222,500	226,000
Shares granted stock options (in Dollars)																$ 80,000
Reissued options				80,000
Exercise price (in Dollars per share)			$ 5	$ 5												$ 5
Contractual life			10 years
Stock options outstanding																		8 years 1 month 2 days		8 years 6 months 29 days
Share-based compensation expense (in Dollars)																		$ 346,549,000	$ 94,099,000
Common Stock [Member]
Equity [Line Items]
Common stock, shares authorized																		300,000,000		19,000,000
warrant exercisable per share (in Dollars per share)																		$ 0.0001		$ 0.0001
Stock options, shares																		1,537,667
Stock options value (in Dollars)										6,000								$ 6,000
Common stock purchase (in Dollars)	$ 8,000							25,000
Proceeds from Issuance of Common Stock (in Dollars)		$ 5,000				$ 1,000	$ 10,000
Additional Paid-in Capital [Member]
Equity [Line Items]
Stock options value (in Dollars)										$ 37,494,000								$ 37,494,000
Common stock purchase (in Dollars)	$ 249,996,000							$ 749,975,000
Proceeds from Issuance of Common Stock (in Dollars)		$ 139,995,000				$ 29,999,000	$ 293,579,000
Preferred Stock [Member]
Equity [Line Items]
Preferred stock value (in Dollars)											23,000
Tranche One [Member]
Equity [Line Items]
Preferred stock including additional paid-in capital (in Dollars)											1,462,146,000
Additional paid-in capital (in Dollars)											1,462,037,000
Tranche One [Member] | Preferred Stock [Member]
Equity [Line Items]
Preferred stock value (in Dollars)											109,000
Tranche Two [Member]
Equity [Line Items]
Preferred stock, shares issued																						349,790
Remaining additional paid-in capital (in Dollars)																						$ 469,207,000
Tranche Two [Member] | Additional Paid-in Capital [Member]
Equity [Line Items]
Additional paid-in capital (in Dollars)																						469,172,000
Tranche Two [Member] | Preferred Stock [Member]
Equity [Line Items]
Preferred stock value (in Dollars)																						$ 35,000
Tranche Three[Member]
Equity [Line Items]
Preferred stock, shares issued																					111,884
Remaining additional paid-in capital (in Dollars)																					$ 150,080,000
Tranche Three[Member] | Additional Paid-in Capital [Member]
Equity [Line Items]
Additional paid-in capital (in Dollars)																					150,069,000
Black-Scholes Option Pricing Model [Member]
Equity [Line Items]
Vesting percentage			25%		25%				25%			25%	25%	25%	25%		25%		25%
Percentage of option vesting for remaining period			75%		75%				75%			75%	75%	75%	75%		75%		75%
Independent Directors [Member]
Equity [Line Items]
Vesting percentage																25%
Percentage of option vesting for remaining period				75%												75%
Equity interest [Member]
Equity [Line Items]
Equity interest								50%
Derivative Liabilities [Member]
Equity [Line Items]
Derivative liabilities at fair value (in Dollars)											$ 55,701,000
Warrant [Member]
Equity [Line Items]
Common stock, shares issued								250,000
Number of common stock warrant purchase	99,998							250,000
Warrant [Member] | Common Stock [Member]
Equity [Line Items]
Common stock, shares issued	83,332
Series seed 1 preferred stock [Member]
Equity [Line Items]
Preferred stock shares authorized																		213,730		213,730
Preferred stock, par value (in Dollars per share)																		$ 0.0001		$ 0.0001
Preferred stock, shares issued																		213,730		213,730
Preferred stock, shares outstanding																		213,730		213,730
Series 2 Preferred Stock [Member]
Equity [Line Items]
Preferred stock shares authorized																		3,635,252		3,635,252
Preferred stock, par value (in Dollars per share)																		$ 0.0001		$ 0.0001
Preferred stock, shares issued																		3,635,252		3,635,252
Preferred stock, shares outstanding																		3,635,252		3,635,252
Series A Preferred Shares [Member]
Equity [Line Items]
Preferred stock shares authorized																		2,982,003		2,982,003
Preferred stock, par value (in Dollars per share)																		$ 0.0001		$ 0.0001
Preferred stock, shares issued				1,861,799												1,861,799		1,861,799		1,861,799
Preferred stock, shares outstanding				1,861,799												1,861,799		1,861,799		1,861,799
Preferred stock value (in Dollars)																		$ 186,000		$ 186,000
Series A Preferred Shares [Member] | Common Stock [Member]
Equity [Line Items]
Number of common stock warrant purchase											231,828
Series A Preferred Shares [Member] | Preferred Stock [Member]
Equity [Line Items]
Stock options value (in Dollars)
Series A Preferred Shares [Member] | Tranche One [Member]
Equity [Line Items]
Preferred stock, shares issued											1,090,029
Series A Preferred Shares [Member] | Tranche Three[Member]
Equity [Line Items]
Preferred stock value (in Dollars)																					$ 11,000
Office and Administration Expenses [Member]
Equity [Line Items]
Share-based compensation expense (in Dollars)																		337,551,000	$ 8,998,000
Research and Development Expense [Member]
Equity [Line Items]
Share-based compensation expense (in Dollars)																		$ 90,271,000	$ 3,828,000

Equity (Details) - Schedule of

Equity (Details) - Schedule of Equity Warrants - Warrants [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Class of Warrant or Right [Line Items]
Outstanding | shares	349,998
Weighted average exercise price | $ / shares	$ 3
August 28 2026 [Member]
Class of Warrant or Right [Line Items]
Outstanding | shares	250,000
Expiry date	Aug. 28, 2026
Weighted average exercise price | $ / shares	$ 3
March 12 2027 [Member]
Class of Warrant or Right [Line Items]
Outstanding | shares	99,998
Expiry date	Mar. 12, 2027
Weighted average exercise price | $ / shares	$ 3

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of Black-Scholes Option Pricing Model	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Minimum [Member]
Equity (Details) - Schedule of Black-Scholes Option Pricing Model [Line Items]
Risk-free interest rate	3.39%	2.81%
Expected life	10 years	10 years
Expected dividend rate	0%	0%
Expected volatility	100%	100%
Forfeiture rate	0%	0%
Maximum [Member]
Equity (Details) - Schedule of Black-Scholes Option Pricing Model [Line Items]
Risk-free interest rate	3.86%	4.07%
Expected life	10 years	10 years
Expected dividend rate	0%	0%
Expected volatility	100%	100%
Forfeiture rate	0%	0%

Equity (Details) - Schedule o_3

Equity (Details) - Schedule of Stock Options - Stock Options [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Equity (Details) - Schedule of Stock Options [Line Items]
Outstanding, Number of stock options beginning	1,366,167	1,133,334
Outstanding, Weighted average exercise price beginning	$ 1.08	$ 0.6
Granted, Number of stock options	234,000	412,000
Granted, Weighted average exercise price	$ 5	$ 2.19
Forfeited, Number of stock options		(137,500)
Forfeited, Weighted average exercise price		$ 0.6
Exercised, Number of stock options	(62,500)	(41,667)
Exercised, Weighted average exercise price	$ 0.6	$ 0.6
Outstanding, Number of stock options Ending	1,537,667	1,366,167
Outstanding, Weighted average exercise price Ending	$ 1.7	$ 1.08

Equity (Details) - Schedule o_4

Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held - Common Stock [Member]	Sep. 30, 2023 $ / shares shares
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	1,537,667
Vested	698,561
Weighted average exercise price (in Dollars per share) | $ / shares	$ 1.7
Stock Option One [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	841,667
Vested	561,117
Expiry date	Feb. 08, 2031
Weighted average exercise price (in Dollars per share) | $ / shares	$ 0.6
Stock Option Two [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	50,000
Vested	33,340
Expiry date	Feb. 27, 2031
Weighted average exercise price (in Dollars per share) | $ / shares	$ 0.6
Stock Option Three [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	45,000
Vested	15,938
Expiry date	Apr. 25, 2032
Weighted average exercise price (in Dollars per share) | $ / shares	$ 0.6
Stock Option Four [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	16,000
Vested	5,000
Expiry date	Jun. 01, 2032
Weighted average exercise price (in Dollars per share) | $ / shares	$ 1.34
Stock Option Five [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	110,000
Vested	32,083
Expiry date	Jul. 01, 2032
Weighted average exercise price (in Dollars per share) | $ / shares	$ 1.34
Stock Option Six [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	100,000
Vested	27,083
Expiry date	Aug. 08, 2032
Weighted average exercise price (in Dollars per share) | $ / shares	$ 1.34
Stock Option Seven [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	16,000
Vested	4,000
Expiry date	Sep. 30, 2032
Weighted average exercise price (in Dollars per share) | $ / shares	$ 1.34
Stock Option Eight [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	80,000
Vested	20,000
Expiry date	Sep. 30, 2032
Weighted average exercise price (in Dollars per share) | $ / shares	$ 5
Stock Option Nine [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	10,000
Vested
Expiry date	Oct. 15, 2032
Weighted average exercise price (in Dollars per share) | $ / shares	$ 1.34
Stock Option Ten [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	10,000
Vested
Expiry date	Nov. 01, 2032
Weighted average exercise price (in Dollars per share) | $ / shares	$ 1.34
Stock Option Eleven [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	5,000
Vested
Expiry date	Nov. 01, 2032
Weighted average exercise price (in Dollars per share) | $ / shares	$ 5
Stock Option Twelve [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	20,000
Vested
Expiry date	Dec. 12, 2032
Weighted average exercise price (in Dollars per share) | $ / shares	$ 5
Stock Option Thirteen [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	10,000
Vested
Expiry date	Feb. 01, 2033
Weighted average exercise price (in Dollars per share) | $ / shares	$ 5
Stock Option Fourteen [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	50,000
Vested
Expiry date	Apr. 16, 2033
Weighted average exercise price (in Dollars per share) | $ / shares	$ 5
Stock Option Fifteen [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	80,000
Vested
Expiry date	May 01, 2033
Weighted average exercise price (in Dollars per share) | $ / shares	$ 5
Stock Option Sixteen [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	80,000
Vested
Expiry date	Jan. 25, 2033
Weighted average exercise price (in Dollars per share) | $ / shares	$ 5
Stock Option Seventeen [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	10,000
Vested
Expiry date	Jun. 27, 2033
Weighted average exercise price (in Dollars per share) | $ / shares	$ 5
Stock Option Eighteen [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	2,500
Vested
Expiry date	Jul. 10, 2033
Weighted average exercise price (in Dollars per share) | $ / shares	$ 5
Stock Option Nineteen [Member]
Equity (Details) - Schedule of Right To Purchase One Common Stock Option Held [Line Items]
Outstanding	1,500
Vested
Expiry date	Jul. 01, 2033
Weighted average exercise price (in Dollars per share) | $ / shares	$ 5

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands								3 Months Ended	9 Months Ended
	Jul. 01, 2023	Jun. 01, 2023	Feb. 01, 2023	Jun. 01, 2022	Apr. 25, 2022	Jul. 20, 2021	Feb. 09, 2021	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Apr. 01, 2023	Mar. 31, 2023	Jan. 06, 2023	Dec. 31, 2022	Oct. 17, 2022
Related Party Transactions (Details) [Line Items]
Percentage of authority control									10%
Stock options granted (in Shares)		160,000					800,000	250,000
Contractual term		10 years				10 years	10 years
Exercise price per share (in Dollars per share)		$ 5				$ 0.6	$ 0.6
Stock options value		$ 420,521				$ 51,014	$ 203,972
Stock Option Cancelled and Reissued (in Shares)		80,000
Unvested options were forfeited (in Shares)															137,500
Remaining vested option (in Shares)															62,500
Share-based compensation expense									$ 346,549	$ 94,099
Weighted average exercise price percentage (in Dollars per share)								$ 1.22		$ 1.22
Due to related party									222,675					$ 142,704
Unsecured amount									12,675					22,705
Equity and debt investment amount									2,000,000
Stock Option [Member]
Related Party Transactions (Details) [Line Items]
Contractual term		10 years
Exercise price per share (in Dollars per share)		$ 5
Share-based compensation expense										$ 1,425
Black-Scholes Option Pricing Model [Member]
Related Party Transactions (Details) [Line Items]
Vesting percentage	25%	25%	25%	25%	25%	25%	25%	25%		25%
Percentage of option vesting for remaining period	75%	75%	75%	75%	75%	75%	75%	75%		75%
Common Stock [Member]
Related Party Transactions (Details) [Line Items]
Exercise price per share (in Dollars per share)		$ 5
Series A Preferred Stock [Member]
Related Party Transactions (Details) [Line Items]
Preferred stock price (in Dollars per share)											$ 3	$ 1.34138
Brenda Buechler [Member]
Related Party Transactions (Details) [Line Items]
Amount of salary paid									159,950	$ 56,803
Employer taxes									17,446	4,303
Christoph Kraneiss [Member]
Related Party Transactions (Details) [Line Items]
Amount of salary paid									148,131	24,354
Employer taxes									13,131	1,854
Two Directors [Member]
Related Party Transactions (Details) [Line Items]
Stock options granted (in Shares)		80,000
Northstrive Companies Inc. [Member]
Related Party Transactions (Details) [Line Items]
Consulting fees									90,000	90,000
Due to related party									210,000					120,000
Jordan Plews [Member]
Related Party Transactions (Details) [Line Items]
Amount of salary paid									168,050	171,721
Employer taxes									18,050	11,720
Accounts payable and accrued liabilities									4,272					2,971
Four Related Parties [Member]
Related Party Transactions (Details) [Line Items]
Stock options granted (in Shares)							200,000
Yi Guo [Member]
Related Party Transactions (Details) [Line Items]
Remaining vested option (in Shares)													62,500
Brenda Buechler, Chief Marketing Officer [Member]
Related Party Transactions (Details) [Line Items]
Stock options granted (in Shares)								150,000
Christoph Kraneiss, Chief Commercial Officer [Member]
Related Party Transactions (Details) [Line Items]
Stock options granted (in Shares)								100,000
Black-Scholes Option Pricing Model [Member]
Related Party Transactions (Details) [Line Items]
Stock options value										264,906
Braeden Lichti [Member]
Related Party Transactions (Details) [Line Items]
Due to related party									222,675					142,705
Accounts payable and accrued liabilities									7,831					1,485
Graydon Bensler [Member]
Related Party Transactions (Details) [Line Items]
Accounts payable and accrued liabilities									7,442					$ 7,165
GB Capital Ltd [Member]
Related Party Transactions (Details) [Line Items]
Consulting fees									$ 63,750	$ 57,998
Related Party [Member]
Related Party Transactions (Details) [Line Items]
Stock options granted (in Shares)						200,000

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of Remuneration of Directors and Key Management Personnel - Directors and Key Management Personnel [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Related Party Transactions (Details) - Schedule of Remuneration of Directors and Key Management Personnel [Line Items]
Consulting fees	$ 51,250	$ 51,250	$ 153,750	$ 147,998
Salaries	159,874	63,784	476,126	252,879
Share-based compensation	124,994	29,860	247,348	80,259
Total	$ 336,118	$ 144,894	$ 877,224	$ 481,136

Related Party Transactions (D_3

Related Party Transactions (Details) - Schedule of Fair Value of the Options Granted to Each Individual and the Related Expense - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Fair Value, Option, Quantitative Disclosures [Line Items]
Individual and the related expense	$ 145,516,000	$ 46,284,000
Grant date fair value of stock options	264,906,000		$ 732,131,000
Braeden Lichti, Former Chairman and President [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Individual and the related expense	5,398,000	11,571,000
Grant date fair value of stock options			50,993,000
Graydon Bensler, CFO and Director [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Individual and the related expense	5,398,000	11,571,000
Grant date fair value of stock options			50,993,000
Jordan Plews, CEO and Director [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Individual and the related expense	5,398,000	11,571,000
Grant date fair value of stock options			50,993,000
Tim Sayed, Chief Medical Officer [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Individual and the related expense	5,398,000	11,571
Grant date fair value of stock options			50,993,000
Jeffrey Parry, Director [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Individual and the related expense	21,177,000
Grant date fair value of stock options			107,669,000
Julie Daley, Director [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Individual and the related expense	56,022,000
Grant date fair value of stock options			210,245,000
Crystal Muilenburg, Director [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Individual and the related expense	$ 46,725,000
Grant date fair value of stock options			$ 210,245,000

Related Party Transactions (D_4

Related Party Transactions (Details) - Schedule of Fair Value Granted to Each Individual and the Related Expense - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value granted to each individual and the related expense	$ 101,832	$ 32,551
Grant date fair value of stock options	264,906		$ 732,131
Brenda Buechler, Chief Marketing Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value granted to each individual and the related expense	53,008	22,189
Grant date fair value of stock options	143,679
Christoph Kraneiss, Chief Commercial Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair value granted to each individual and the related expense	48,824	$ 10,362
Grant date fair value of stock options	$ 121,227

Commitments and Contingencies (

Commitments and Contingencies (Details) - 9 months ended Sep. 30, 2023	USD ($)	CAD ($)
Commitments and Contingencies [Abstract]
Final Settlement	$ 9,225	$ 12,500

Concentrations (Details)

Concentrations (Details) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Concentrations (Details) [Line Items]
Due from customer	$ 49
Customer deposits	54,853,000		10,172,000
Largest Customer [Member]
Concentrations (Details) [Line Items]
Customer deposits			$ 5,992
Revenue [Member] | Customer Concentration Risk [Member] | Largest customers [Member]
Concentrations (Details) [Line Items]
Revenue	14%
Revenue [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Concentrations (Details) [Line Items]
Revenue		55%
Three Suppliers [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]
Concentrations (Details) [Line Items]
Revenue	66%	72%

Concentrations (Details) - Sche

Concentrations (Details) - Schedule of Suppliers Percentage of Cost - Accounts Payable [Member] - Supplier Concentration Risk [Member]	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Supplier 1 [Member]
Concentration Risk [Line Items]
Total	26%	46%
Supplier 2 [Member]
Concentration Risk [Line Items]
Total	23%	14%
Supplier 2 [Member]
Concentration Risk [Line Items]
Total	17%	12%
Supplier 3 [Member]
Concentration Risk [Line Items]
Total	66%	72%